11 results on '"Kirsten Jost"'
Search Results
2. Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen
- Author
-
Carlos Gomez-Roca, Yong-Mei Yin, Manfred P. Wirth, Hein van Poppel, Mathias Freund, Matthias W. Beckmann, Kourong Miao, Inken Hilgendorf, Eva Respondek-Dryba, Stefan Pahl, Susanne Decker, Christian Junghanss, Isrid Sturm, Susanne Osanto, Kirsten Jost, Lijuan Chen, Jean-Charles Soria, Xifeng Qian, Rolf Kreienberg, Benjamin Besse, Christoph Kahl, Su-Yu Miao, Ina Kopp, Hongfeng Guo, Virginie Prulière-Escabasse, Carsten Hirt, Malte Leithäuser, Yong-Qian Shu, Guo-Liang Wang, Christophe Massard, Christoph Röllig, Diethelm Wallwiener, L. Weißbach, Run Zhang, Achim Wöckel, Susanne Weinbrenner, Xiao-Dong Li, Monika Nothacker, Annegret Kunitz, Jianyong Li, Juliane Strack, Günter Ollenschläger, Eva Wardelmann, Hanxin Wu, Paulo N. Lopes, Walter Jonat, Falk Thiel, Estelle Escudier, Rong Wang, Sebastian Rohde, Claudia Reichelt, André, Hairong Qiu, Michael Gnant, Manfred Gaspar, Michael P. Lux, Petr Podrabsky, Li Yang, Coste, and Jianfu Zhang
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2010
- Full Text
- View/download PDF
3. Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation
- Author
-
Kirsten Jost, Christian Junghanss, M. Maruschke, D. Wolff, C. Aepinus, Mathias Freund, Friedrich Prall, H. Riemer, Malte Leithäuser, Inken Hilgendorf, and Christoph Kahl
- Subjects
Voriconazole ,Transplantation ,Posaconazole ,medicine.medical_specialty ,business.industry ,medicine.disease ,Aspergillosis ,Surgery ,chemistry.chemical_compound ,surgical procedures, operative ,Infectious Diseases ,Graft-versus-host disease ,chemistry ,immune system diseases ,medicine ,Zygomycosis ,Caspofungin ,business ,Multiple myeloma ,medicine.drug - Abstract
M. Leithauser, C. Kahl, C. Aepinus, F. Prall, M. Maruschke, H. Riemer, D. Wolff, K. Jost, I. Hilgendorf, M. Freund, C. Junghanss. Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation Transpl Infect Dis 2010: 12: 251–257. All rights reserved Abstract: Invasive mold infections are a threat to immunosuppressed patients such as patients with graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (SCT). Up to 10% of SCT recipients develop invasive aspergillosis (IA). Invasive zygomycosis (IZ) may occur during treatment against IA. Here we report 4 SCT patients with GVHD diagnosed with IZ. All patients had received myeloablative hematopoietic SCT and developed chronic GVHD requiring systemic immunosuppression. Underlying diseases were acute lymphocytic leukemia (2), osteomyelofibrosis, and multiple myeloma. All patients had developed pulmonary infiltration that led to initiation of antifungal therapy. Treatment for IA was voriconazole, caspofungin, or itraconazole. Organs involved with zygomycosis were lung, nasal sinus, skin, and kidney. Treatment with liposomal amphotericin and posaconazole was initiated in all patients, and 2 patients also had surgical debridement as well. Despite intensive treatment, no patient survived. IZ is becoming more common in patients with GVHD on successful treatment for IA. Even non-specific symptoms are suspicious in this group of patients and need to be evaluated by vigorous diagnostics. Despite effective antifungals and surgical intervention, the prognosis is grim in patients with active GVHD, as immunoreconstitution is mandatory for successful management.
- Published
- 2009
- Full Text
- View/download PDF
4. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer
- Author
-
Eberhard Schwinger, Kirsten Jost, Sven Opitz, Horst‐Werner Stürzbecher, Alfred Ch. Feller, Stefan Krüger, Willem Hamdorf, Heiko Maacke, Klaus Diedrich, Antje Lopens, and Wilhelm Henning
- Subjects
Electrophoresis ,Cancer Research ,medicine.medical_specialty ,Pathology ,Mammary gland ,RAD51 ,Down-Regulation ,Breast Neoplasms ,Biology ,Pathogenesis ,Breast cancer ,medicine ,Humans ,skin and connective tissue diseases ,Grading (tumors) ,Neoplasm Staging ,Cell Nucleus ,BRCA1 Protein ,Carcinoma, Ductal, Breast ,Cancer ,Middle Aged ,Ductal carcinoma ,medicine.disease ,Neoplasm Proteins ,Up-Regulation ,DNA-Binding Proteins ,medicine.anatomical_structure ,Oncology ,Cancer research ,Female ,Histopathology ,Rad51 Recombinase - Abstract
Breast cancer is a major cause of cancer-related death in women. BRCA1 tumour-suppressor function is abolished in sporadic breast cancer by down-regulation of the protein level. This down-regulation inversely correlates with tumour grading. BRCA1 is part of a multiprotein complex, which also contains the recombination factor Rad51. Here we describe that in contrast to BRCA1, histological grading of sporadic invasive ductal breast cancer significantly correlates with over-expression of wild-type Rad51. These data suggest that in addition to the absence of the tumour-suppressor protein BRCA1, over-expression of wild-type Rad51 also contributes to the pathogenesis of a significant percentage of sporadic breast cancers and that other mechanisms than mutations must be responsible for this altered expression. Int. J. Cancer 88:907–913, 2000. © 2000 Wiley-Liss, Inc.
- Published
- 2000
- Full Text
- View/download PDF
5. Perforation of the Superior Vena Cava – a Rare Complication of Central Venous Catheters
- Author
-
Christina Groβe-Thie, Holger Andree, Kirsten Jost, Mathias Freund, Malte Leithäuser, Inken Hilgendorf, Christian Junghanss, Jochen Casper, and Anne Bartolomaeus
- Subjects
Adult ,Catheterization, Central Venous ,Cancer Research ,medicine.medical_specialty ,Vena Cava, Superior ,Pleural effusion ,medicine.medical_treatment ,Perforation (oil well) ,Wounds, Penetrating ,Rare Diseases ,Superior vena cava ,medicine ,Acute chest pain ,Humans ,In patient ,Chemotherapy ,business.industry ,Hematology ,General Medicine ,equipment and supplies ,medicine.disease ,Surgery ,Oncology ,Drainage ,Female ,Radiology ,Complication ,business ,Central venous catheter - Abstract
Background: Central venous catheters (CVC) guarantee a reliable venous access and are an indispensable part of the therapy in patients with hematologic malignancies. On the other hand, they contribute significantly to the therapy-related morbidity in this group of patients. The most common complications are catheter-associated infections or thromboses. Here we report on the rare, but potentially life-threatening case of a vessel wall perforation by a CVC. Case Report: A 29-year-old female with newly diagnosed acute lymphoblastic leukemia had a CVC inserted via the left subclavian vein. After two weeks she complained about acute chest pain. Radiology revealed right-sided pleural effusion which was due to a vena cava superior vessel wall perforation by the CVC. Chemotherapy extravasation was excluded by pleural fluid analyses. Conclusion: A vessel wall perforation by a CVC is a rare and often late CVC complication with usually unspecific symptoms. Especially patients with leftsided, large-bore catheters are at risk. Awareness of this complication and immediate therapy are essential. We discuss the possible mechanisms and treatment options of this rare CVC complication.
- Published
- 2008
- Full Text
- View/download PDF
6. Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: a multicenter randomized phase III study
- Author
-
Annette Kopp-Schneider, Andreas Hochhaus, Wolfgang Queisser, C. Wojatschek, Y. Dencausse, Kirsten Jost, Lutz Edler, Lindemann W, Fackler-Schwalbe I, D. Bornbusch, G. Dietrich, M. Gonnermann, R.D. Hofheinz, J. Sturm, G. Hartung, and H. Eschenburg
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Edrecolomab ,Antineoplastic Agents ,Gastroenterology ,Risk Assessment ,Severity of Illness Index ,Disease-Free Survival ,Cohort Studies ,Antibodies, Monoclonal, Murine-Derived ,Risk Factors ,Internal medicine ,Germany ,Clinical endpoint ,Adjuvant therapy ,Medicine ,Humans ,Survival analysis ,Aged ,Neoplasm Staging ,Aged, 80 and over ,business.industry ,Antibodies, Monoclonal ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Survival Analysis ,Surgery ,Discontinuation ,Treatment Outcome ,Oncology ,Chemotherapy, Adjuvant ,Cohort ,Colonic Neoplasms ,Female ,business ,medicine.drug ,Cohort study - Abstract
iBackground: In a phase III study recruiting patients with stage II colon cancer the effect of adjuvant therapy with edrecolomab, a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, was compared to observation alone. Patients and Methods: From January 1997 until July 2000 a total of 377 patients were postoperatively stratified according to tumor stage (T3 vs. T4) and center, and randomly allocated to either treatment with edrecolomab (cohort A, n = 183) or observation (cohort B, n = 194). Patients in cohort A received a total of 900 mg edrecolomab. The study was terminated prematurely because of discontinuation of drug supply in Germany. Results: 305 patients were eligible for the primary endpoint of overall survival and 282 patients for disease-free survival. After a median follow-up of 42 months overall survival and disease-free survival were not significantly different. Toxicity was mild. Conclusions: In the present study, postoperative adjuvant treatment with edrecolomab in patients with resected stage II colon cancer did not improve overall or disease-free survival.
- Published
- 2005
7. EXTREME-Studie definiert neue Referenztherapie mit Cetuximab
- Author
-
Thomas Lowe, Alberto Sobrero, Qixiang Shao, Sabine K. Mai, Anthony S. Stein, Dietmar Dinter, Jan Peter Pintoffl, Xiaopeng Xu, Grit Welzel, Steffen J. Diehl, Jia Tong, George Somlo, Valeria Andretta, Qian Jiang, Brigitte Hermann, Salah-Eddin Al-Batran, Thehang Luu, Andreas Bembenek, Holger Andree, Huaxi Xu, Malte Leithäuser, Martin Holtmann, Mathias Freund, Shengjun Wang, Regina G. H. Beets-Tan, Min Yang, Tsvetomir Tomov, Stephen Shibata, Chaoming Mao, Mark Hartel, Georg F.A.B. Kaehler, Ralf-Dieter Hofheinz, Jie Ma, Long Li, Smita Bhatia, Christina Groβe-Thie, Markus Bohrer, Jochen Casper, Alexander M.M. Eggermont, Johannes H. W. de Wilt, Kirsten Jost, Anne Bartolomaeus, Geerard L. Beets, Hendrik Kröning, Thomas Höhler, Inken Hilgendorf, Gufeng Qiu, Christian Junghanss, Carsten Bokemeyer, Robert Siegel, Wolfgang Neff, Jörg T. Hartmann, Jeannie Shen, Ulrich Beyer, and Frederik Wenz
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2008
- Full Text
- View/download PDF
8. Cetuximab: Auf dem Weg zur individualisierten Erstlinientherapie
- Author
-
George Somlo, Alberto Sobrero, Holger Andree, Wolfgang Neff, Xiaopeng Xu, Mark Hartel, Dietmar Dinter, Thomas Lowe, Markus Bohrer, Thehang Luu, Christina Groβe-Thie, Jochen Casper, Alexander M.M. Eggermont, Salah-Eddin Al-Batran, Gufeng Qiu, Johannes H. W. de Wilt, Hendrik Kröning, Thomas Höhler, Martin Holtmann, Inken Hilgendorf, Tsvetomir Tomov, Jia Tong, Frederik Wenz, Qian Jiang, Geerard L. Beets, Long Li, Andreas Bembenek, Mathias Freund, Jörg T. Hartmann, Ralf-Dieter Hofheinz, Huaxi Xu, Jeannie Shen, Robert Siegel, Valeria Andretta, Min Yang, Shengjun Wang, Chaoming Mao, Ulrich Beyer, Anne Bartolomaeus, Jie Ma, Carsten Bokemeyer, Brigitte Hermann, Steffen J. Diehl, Grit Welzel, Regina G. H. Beets-Tan, Christian Junghanss, Kirsten Jost, Qixiang Shao, Sabine K. Mai, Anthony S. Stein, Malte Leithäuser, Georg F.A.B. Kaehler, Stephen Shibata, Smita Bhatia, and Jan Peter Pintoffl
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2008
- Full Text
- View/download PDF
9. Multimodal Therapy for Localized Spinal Epidural Follicular Lymphoma
- Author
-
Carsten Hirt, Inken Hilgendorf, Susanne Decker, Mathias Freund, Christoph Kahl, Christian Junghanss, Malte Leithäuser, Eva Respondek-Dryba, Kirsten Jost, Sebastian Rohde, and Dietrich Gläser
- Subjects
Adult ,Cancer Research ,Pathology ,medicine.medical_specialty ,Follicular lymphoma ,Disease-Free Survival ,Thoracic Vertebrae ,Malignant lymphoma ,Myelopathy ,immune system diseases ,Spinal cord compression ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,Lymphoma, Follicular ,business.industry ,Laminectomy ,Multimodal therapy ,Hematology ,General Medicine ,Middle Aged ,Decompression, Surgical ,medicine.disease ,Combined Modality Therapy ,Magnetic Resonance Imaging ,Lymphoma ,Spinal epidural ,Oncology ,Female ,Radiotherapy, Adjuvant ,Epidural Neoplasms ,business ,Spinal Cord Compression ,Follow-Up Studies - Abstract
Myelopathy due to epidural spinal cord compression is rare in patients with malignant lymphoma and most of these patients are diagnosed with high-grade lymphoma. An epidural growth of low-grade lymphoma is even more unusual. Due to this low incidence, therapeutic experience for this entity is limited.We report the outcome of 3 consecutive patients with primary spinal epidural follicular lymphoma (FL). Due to the clinical disorders of the patients and despite the localized disease, we used an intensive multimodal therapy concept consisting of spinal decompression, systemic (immuno)chemotherapy and local irradiation. All patients improved in their medical condition; 2 achieved a complete remission, 1 of these with long-term remission.In contrast to the established irradiation therapy for early-stage FL, an intensive multimodal therapy concept should be initiated in patients with primary spinal epidural FL. With this approach, a fast improvement of the symptoms and long-term disease-free survival is possible.
- Published
- 2010
- Full Text
- View/download PDF
10. Steven Karger (1959–2008)
- Author
-
Holger Andree, Mathias Freund, Grit Welzel, Ralf-Dieter Hofheinz, Qixiang Shao, Sabine K. Mai, Anthony S. Stein, Huaxi Xu, Alberto Sobrero, Inken Hilgendorf, Hendrik Kröning, Thomas Höhler, Christian Junghanss, Stephen Shibata, Gufeng Qiu, Georg F.A.B. Kaehler, Salah-Eddin Al-Batran, Kirsten Jost, Jie Ma, Xiaopeng Xu, Carsten Bokemeyer, Smita Bhatia, Thehang Luu, Malte Leithäuser, Min Yang, Chaoming Mao, Jia Tong, Steffen J. Diehl, George Somlo, Frederik Wenz, Jan Peter Pintoffl, Andreas Bembenek, Regina G. H. Beets-Tan, Wolfgang Neff, Martin Holtmann, Tsvetomir Tomov, Geerard L. Beets, Jeannie Shen, Jochen Casper, Markus Bohrer, Robert Siegel, Anne Bartolomaeus, Qian Jiang, Long Li, Brigitte Hermann, Ulrich Beyer, Jörg T. Hartmann, Valeria Andretta, Shengjun Wang, Thomas Lowe, Mark Hartel, Christina Groβe-Thie, Alexander M.M. Eggermont, Johannes H. W. de Wilt, and Dietmar Dinter
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2008
- Full Text
- View/download PDF
11. Die Tumorhistologie als prädiktiver Faktor in der NSCLC-Therapie
- Author
-
Mark Hartel, Qixiang Shao, Sabine K. Mai, Anthony S. Stein, Christina Groβe-Thie, Kirsten Jost, George Somlo, Jörg T. Hartmann, Holger Andree, Geerard L. Beets, Mathias Freund, Xiaopeng Xu, Long Li, Hendrik Kröning, Thomas Höhler, Steffen J. Diehl, Ralf-Dieter Hofheinz, Salah-Eddin Al-Batran, Alexander M.M. Eggermont, Johannes H. W. de Wilt, Huaxi Xu, Gufeng Qiu, Inken Hilgendorf, Regina G. H. Beets-Tan, Christian Junghanss, Thehang Luu, Frederik Wenz, Markus Bohrer, Jan Peter Pintoffl, Jie Ma, Jeannie Shen, Thomas Lowe, Martin Holtmann, Andreas Bembenek, Robert Siegel, Malte Leithäuser, Tsvetomir Tomov, Stephen Shibata, Ulrich Beyer, Smita Bhatia, Anne Bartolomaeus, Wolfgang Neff, Brigitte Hermann, Jia Tong, Carsten Bokemeyer, Grit Welzel, Jochen Casper, Georg F.A.B. Kaehler, Qian Jiang, Shengjun Wang, Valeria Andretta, Min Yang, Chaoming Mao, Dietmar Dinter, and Alberto Sobrero
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.